Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 5, 2006 - Issue 5
Submit an article Journal homepage
126
Views
10
CrossRef citations to date
0
Altmetric
Review

Safety of neuraminidase inhibitors for influenza

Mark Jones Biostatistician, University of Queensland, Princess Alexandra Hospital, School of Population Health, Woolloongabba, Queensland 4102, Australia. [email protected]
&
Chis Del Mar Dean of Health Sciences and Medicine, Bond University, Faculty of Health Sciences and Medicine, Gold Coast, Queensland 4229, Australia. [email protected]
Pages 603-608 | Published online: 15 Aug 2006

Bibliography

  • JEFFERSON T, DEMICHELI V, RIVETTI D, JONES M, DI PIETRANTON J C, RIVETTI A: Antivirals for influenza in healthy adults: systematic review. Lancet (2006) 367:303-313.
  • MATHESON NJ, SYMMONDS-ABRAHAMS M, SHEIKH A, SHEPPERD S, HARNDEN A: Neuraminidase inhibitors for preventing and treating influenza in children. Cochrane Database Syst. Rev. (2003) Issue 3.
  • PAPANIKOLAOU P, CHRISTIDI G, IOANNIDIS J: Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ (2006) 174:635-641.
  • TURNER D, WAILLO A, NICHOLSON K, COOPER N, SUTTON A, ABRAMS K: Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol. Assess. (2003) 7(35):1-170.
  • HAYDEN FG, ATMAR RL, SCHILLING M et al.: Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N. Engl. J. Med. (1999) 341(18):1336-1343.
  • KASHIWAGI S, KUDOH S, WATANABE A, YOSHIMURA I: Efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir for prophylaxis against influenza: placebo-controlled double-blind multicenter Phase III trial. J. Jpn. Assoc. Infect. Dis. (2000) 74(12):1062-1076.
  • LI L, CAI B, WANG M, ZHU Y: A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China. Chin. Med. J. (2003) 116(1):44-48.
  • KASHIWAGI S, KUDOH S, WATANABE A, YOSHIMURA I: Clinical efficacy and safety of the selective oral neuraminidase inhibitor oseltamivir in treating acute influenza: placebo-controlled double-blind multicenter Phase III trial. J. Jpn. Assoc. Infect. Dis. (2000) 74(12):1044-1061.
  • TREANOR JJ, HAYDEN FG, VROOMAN PS et al.: Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA (2000) 283(8):1016-1024.
  • WHITLEY R, DUTKOWSKI R, IPE D, WARD P: Safety and acceptability of oseltamivir liquid formulation in the treatment of influenza in children aged 1 to 12 years. 9th International Congress on Infectious Diseases. Buenos Aires, Argentina (2000).
  • WHITLEY RJ, HAYDEN FG, REISINGER KS et al.: Oral oseltamivir treatment of influenza in children. Pediatr. Infect. Dis. J. (2001) 20(2):127-133.
  • THE MIST (MANAGEMENT OF INFLUENZA IN THE SOUTHERN HEMISPHERE TRIALISTS) STUDY GROUP: Randomised trial of efficacy and safety of inhaled Zanamivir in treatment of influenza A and B virus infection. Lancet (1998) 352:1877-1085.
  • PUHAKKA T, LEHTI H, VAINIONPAEAE R et al.: Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand. J. Infect. Dis. (2003) 35(1):52-58.
  • MATSUMOTO K, OGAWA N, NEROME K et al.: Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan GG167 Group. Antiviral Therapy (1999) 4(2):61-68.
  • MONTO AS, FLEMING DM, HENRY D et al.: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J. Infect. Dis. (1999) 180(2):254-261.
  • MAKELA MJ, PAUKSENS K, ROSTILA T et al.: Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J. Infect. (2000) 40(1):42-48.
  • HEDRICK JA, BARZILAI A, BEHRE U et al.: Zanamivir for treatment of symptomatic influenza A and B infection in children 5 to 12 years of age: a randomized controlled trial. Pediatr. Infect. Dis. J. (2000) 19(5):410-417.

Websites

  • http://www.who.int/mediacentre/factsheets/fs211/en World Health OrganizationInfluenza fact sheet.Number 211 (2003).
  • http://www.fda.gov/cder/drug/infopage/tamiflu/default.htm US Food and Drug Administration: Tamiflu (oseltamivir phosphate) (2005).
  • http://www.fda.gov/cder/news/relenza/default.htm US Food and Drug Administration: Relenza (zanamivir) (2006).
  • http://www.emea.eu.int/humandocs/Humans/EPAR/tamiflu/tamiflu.htm European Medicines Agency: European Public Assessment Report (2006).
  • http://www.emea.eu.int/pdfs/human/pandemicinfluenza/33997205.pdf European Medicines Agency: Summary Report: Review on influenza antiviral medicinal products for potential use during a pandemic (2005).
  • http://www.tamiflu.com/safety.asp Roche Laboratories, Inc.: Tamiflu safety information (2006).
  • http://www.relenza.com/40_SafetyInfo.html GlaxoSmithKline: Important safety information about Relenza (2006).
  • http://www.who.int/csr/disease/avian_influenza/guidelines/pharmamanagement/en/index.html. WHO: Rapid Advice Guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.